Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
March 12, 2019
Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis
DUBLIN, March 12, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2b/3 ...
March 12, 2019
Neovasc Announces Agreements to Exchange Outstanding Warrants for Shares
VANCOUVER, March 12, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN) announced today that it has entered into exchange agreements ("Exchange Agreements") with ...
March 12, 2019
Vermillion to Report Fourth Quarter and Year End 2018 Financial Results on Thursday, March 28
AUSTIN, Texas, March 12, 2019 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will ...
March 12, 2019
Onxeo Reports Full-Year 2018 Financial Results and Provides Business Update
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting ...
March 12, 2019
Altimmune Announces Closing of $14 Million Registered Direct Offering
GAITHERSBURG, Md., March 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the closing of the previously announced registered direct ...
March 12, 2019
Neovasc Announces Proposed Public Offering of Common Shares
VANCOUVER , March 12, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today that it has commenced a ...
March 12, 2019
Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2018
SAN DIEGO and TORONTO, March 12, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing ...
March 12, 2019
Anchiano Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
CAMBRIDGE, Mass., March 12, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and ...
March 11, 2019
Genkyotex Announces Completion of 24-Week Treatment Period of Its Phase 2 Trial with GKT831 in Primary Biliary Cholangitis
Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR0011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that the last patient ...
March 11, 2019
Celyad to Host R&D Day and Webcast on Monday, March 18 in New York City
MONT-SAINT-GUIBERT, Belgium, March 11, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of ...
March 11, 2019
Saniona initiates Phase 2a Tesomet clinical study in hypothalamic obesity patients
Saniona (SANION.ST), a biotech company focused on the central nervous system and eating disorders, announced today that it has recruited the first patient in a ...
March 11, 2019
Orphazyme to present at Cowen & Co Annual Health Care Conference
Copenhagen, Denmark, March 11, 2019 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders ...
March 11, 2019
Spring Bank Pharmaceuticals Reports 2018 Fourth Quarter and Full-Year Financial Results and Corporate Highlights
HOPKINTON, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
March 11, 2019
Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001
SEOUL, South Korea and SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics, Inc. (SRNE) announced today that ImmuneOncia, ...
March 11, 2019
Athenex, Inc. Announces Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update
BUFFALO, N.Y., March 11, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
March 11, 2019
RedHill Biopharma to Present at the 31st Annual ROTH Conference
TEL-AVIV, Israel and RALEIGH, N.C., March 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
March 11, 2019
Orchard Therapeutics Announces Acceptance of OTL-200 Abstract for MLD at the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT)
BOSTON and LONDON, March 11, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with ...
March 11, 2019
Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-APOC3, an RNAi-based ...
March 11, 2019
Tyme Technologies To Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019
NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced that management will present ...
March 11, 2019
Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit
PALO ALTO, Calif., March 11, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare ...
Page 7 of 138